Claims
- 1. A method of diagnosing Alzheimer's disease in a subject in need thereof comprising:
(a) obtaining a test sample from a subject wherein the test sample contains an Aβ peptide and a binding protein; (b) contacting the test sample with a dissociation reagent thereby thoroughly dissociating the Aβ peptide from the binding protein; and (c) measuring the quantity of Aβ peptide in the test sample.
- 2. The method of claim 1, wherein the test sample is selected from the group consisting of red blood cells, white blood cells, platelets, ascites, urine, saliva, olfactory neuroepithelia, skin fibroblasts, and cerebrospinal fluid.
- 3. The method of claim 1, wherein the Aβ peptide is selected from the group consisting of β-amyloid1-42 and Aβ3pE.
- 4. The method of claim 1 wherein the dissociation reagent is selected from the group consisting of formic acid, hydrochloric acid, acetic acid, sulfuric acid, sodium hydroxide, ethanol, methanol, DMSO, DMF, Triton X-100, Tween 20, Tween 80, Sodium dodecyl sulfate (SDS), and raloxifene.
- 5. The method of claim 1 wherein the subject is suffering from cognitive impairment and/or other clinical manifestations sufficient to warrant a possible diagnosis of Alzheimer's disease.
- 6. The method of claim 1 wherein the subject is suspected of developing Alzheimer's disease in the future because of family history or genetic screening.
- 7. The method of claim 1 wherein the subject requests a diagnostic for Alzheimer's disease, or a diagnostic is recommended by a physician, because of the subject's age, or because of suspected early signs of forgetfulness or other possible loss of cognitive function.
- 8. The method of claim 1 wherein the subject's relative propensity to develop full Alzheimer's disease is monitored periodically, with increasing levels of β-amyloid1-42 or Aβ3pE over time indicating an increased propensity of developing Alzheimer's disease.
- 9. An immunoassay diagnostic kit useful for diagnosing Alzheimer's disease according to the method of claim 1 comprising a package containing;
(a) a dissociation reagent (b) an affinity capture reagent, and (c) an affinity label reagent.
- 10. The immunoassay diagnostic kit of claim 9 further comprising immunoassay control reagents.
- 11. A method of diagnosing Alzheimer's disease in a subject in need thereof comprising:
(a) obtaining a test sample from a subject wherein the test sample contains an Aβ peptide and a binding protein; (b) contacting the test sample with a dissociation reagent thereby thoroughly dissociating the Aβ peptide from the binding protein; (c) contacting the test sample with a neutralizing reagent; and (d) measuring the quantity of Aβ peptide in the test sample.
- 12. The method of claim 11, wherein the test sample is selected from the group consisting of red blood cells, white blood cells, platelets, ascites, urine, saliva, olfactory neuroepithelia, skin fibroblasts, and cerebrospinal fluid.
- 13. The method of claim 11, wherein the Aβ peptide is selected from the group consisting of β-amyloid1-42 and Aβ3pE.
- 14. The method of claim 11 wherein the dissociation reagent is selected from the group consisting of formic acid, hydrochloric acid, acetic acid, sulfuric acid, sodium hydroxide, ethanol, methanol, DMSO, DMF, Triton X-100, Tween 20, Tween 80, Sodium dodecyl sulfate (SDS), and raloxifene.
- 15. The method of claim 11 wherein the subject is suffering from cognitive impairment and/or other clinical manifestations sufficient to warrant a possible diagnosis of Alzheimer's disease.
- 16. The method of claim 11 wherein the subject is suspected of developing Alzheimer's disease in the future because of family history or genetic screening.
- 17. The method of claim 11 wherein the subject requests a diagnostic for Alzheimer's disease, or a diagnostic is recommended by a physician, because of the subject's age, or because of suspected early signs of forgetfulness or other possible loss of cognitive function.
- 18. The method of claim 11 wherein the subject's relative propensity to develop full Alzheimer's disease is monitored periodically, with increasing levels of β-amyloid1-42 or Aβ3pE over time indicating an increased propensity of developing Alzheimer's disease.
- 19. An immunoassay diagnostic kit useful for diagnosing Alzheimer's disease according to the method of claim 11 comprising a package containing;
(a) a dissociation reagent (b) a neutralization reagent, (c) an affinity capture reagent, (d) an affinity label reagent.
- 20. The immunoassay diagnostic kit of claim 19 further comprising immunoassay control reagents.
- 21. A method of diagnosing Alzheimer's disease in a subject in need thereof comprising:
(a) obtaining a test sample from a subject wherein the test sample is selected from the group consisting of red blood cells, white blood cells, platelets, ascites, urine, saliva, olfactory neuroepithelia, skin fibroblasts, and cerebrospinal fluid, and the test sample contains a binding protein and an Aβ peptide selected from the group consisting of β-amyloid1-42 and Aβ3pE; (b) contacting the test sample with a dissociation reagent selected from the group consisting of formic acid, hydrochloric acid, acetic acid, sulfuric acid, sodium hydroxide, ethanol, methanol, DMSO, DMF, Triton X-100, Tween 20, Tween 80, Sodium dodecyl sulfate (SDS), and raloxifene, thereby thoroughly dissociating the Aβ peptide from the binding protein; and (c) measuring the quantity of Aβ peptide in the test sample.
- 22. A method of diagnosing Alzheimer's disease in a subject in need thereof comprising:
(a) obtaining a test sample from a subject wherein the test sample is selected from the group consisting of red blood cells, white blood cells, platelets, ascites, urine, saliva, olfactory neuroepithelia, skin fibroblasts, and cerebrospinal fluid, and the test sample contains a binding protein and an Aβ peptide selected from the group consisting of β-amyloid1-42 and Aβ3pE; (b) contacting the test sample with a dissociation reagent selected from the group consisting of formic acid, hydrochloric acid, acetic acid, sulfuric acid, sodium hydroxide, thereby thoroughly dissociating the Aβ peptide from the binding protein; (c) contacting the test sample with a neutralizing reagent; and (d) measuring the quantity of Aβ peptide in the test sample by immunoassay.
- 23. The method of claim 21 wherein the quantity of Aβ peptide is detected using a labeled compound selected from the group consisting of horseradish peroxidase, alkaline phosphatase, luciferase, fluorescein (FITC), rhodamine, R-phycoerythrin (PE), and Alexa™ dyes (Molecular Probes).
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from United States provisional application Serial No. 60/179,976, filed Feb. 3, 2000, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60179976 |
Feb 2000 |
US |